Central Idea
- India has achieved a significant milestone in the field of cancer treatment with the approval of NexCAR19, its first indigenous CAR-T Cell Therapy, by the Central Drugs Standard Control Organisation (CDSCO).
- Developed by ImmunoACT, an incubated company of IIT Bombay, NexCAR19 is set to transform cancer treatment in India and make it more affordable.
What is CAR-T Cell Therapy?
- Revolutionary Approach: CAR-T cell therapy involves modifying T-cells, a type of white blood cell, into potent cancer-fighting cells.
- Targeting Cancer: These genetically enhanced cells are reintroduced into the patient’s body, where they identify and eliminate cancer cells, particularly effective against blood cancers like leukemia and lymphomas.
- Game-Changer: Unlike chemotherapy or immunotherapy, CAR-T therapy offers the potential for a cure and lifelong benefits, making it a transformative treatment option.
NexCAR19: India’s Indigenously Developed CAR-T Therapy
- NexCAR19 is designed to target cancer cells carrying the CD19 protein, a marker on cancer cells, enhancing precision in treatment.
- India joins a select group of nations with its own CAR-T and gene therapy platform, reducing dependence on imports.
- Initially approved for patients aged 15 and above with B-cell lymphomas who did not respond to standard treatments, leading to relapse or recurrence.
Effectiveness and Unique Features
- Approximately 70% of patients respond to NexCAR19 treatment, with some achieving complete remission.
- Lab and animal studies indicate lower drug-related toxicities, including reduced neurotoxicity and Cytokine Release Syndrome (CRS).
- Trials for paediatric patients are underway at Tata Memorial Hospital, ensuring broader applicability.
Availability and Affordability
- ImmunoACT is in the process of securing licenses and partnering with hospitals, including Tata Memorial, Nanavati, Fortis, and Jaslok, across multiple cities.
- CAR-T therapy is expected to be available in a matter of weeks to a few months, pending final government approvals.
- Initially priced at Rs 30-40 lakh, ImmunoACT aims to eventually reduce the cost to Rs 10-20 lakh, making the therapy more accessible.
- Approval by regulatory agencies like CDSCO should lead to insurance coverage, but the extent may vary, and discussions with insurers and the government are ongoing.
